AstraZeneca withdraws NYSE listing for 0.700% Notes

AstraZeneca PLC notified the New York Stock Exchange of the voluntary withdrawal of its 0.700% Notes due 2026 from listing and registration on the NYSE.

Accepted by SEC EDGAR 04/08/2026 - 02:20 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

AstraZeneca PLC notified the New York Stock Exchange of the voluntary withdrawal of its 0.700% Notes due 2026 from listing and registration on the NYSE. The Exchange certified compliance with Rule 12d2-2 and the issuer complied with the Exchange rules governing voluntary withdrawal.

Key Figures

Commission File Number: 001-11960 Coupon: 0.700% Maturity: due 2026 +1 more

4 metrics

Commission File Number 001-11960 Form 25 cover data

Coupon 0.700% Notes identified as "0.700% Notes due 2026"

Maturity due 2026 Maturity year of the identified notes

Expiry reference March 31, 2018 Expires date printed on form header

Key Terms

Form 25, 17 CFR 240.12d2-2, voluntary withdrawal

3 terms

Form 25 regulatory

"FORM 25 NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION"

A Form 25 is an official filing with the U.S. Securities and Exchange Commission used to remove a company's stock or other security from a national exchange list. Investors should care because delisting often means less visibility, lower trading volume and wider price swings—similar to a product moving from a major supermarket to a small local market, which can make buying, selling and valuing the security more difficult.

17 CFR 240.12d2-2 regulatory

"Pursuant to 17 CFR 240.12d2-2(b) ... 12d2-2(c)"

A U.S. Securities and Exchange Commission rule that describes the conditions and procedural steps for a security to be removed from public registration or reporting under the Securities Exchange Act of 1934. For investors, it matters because it explains when a company’s shares can stop being subject to regular disclosure and exchange listing rules — similar to knowing when a publicly tracked product will be discontinued and no longer send updates, which affects transparency and liquidity.

voluntary withdrawal market

"governing the voluntary withdrawal of the class of securities from listing"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Why did AstraZeneca (AZN) remove the 0.700% Notes due 2026 from the NYSE?

The filing states the withdrawal is voluntary. The Exchange and issuer certified compliance with 17 CFR 240.12d2-2 and NYSE rules governing voluntary withdrawal; no further rationale or financial details are provided in the excerpt.

Will AstraZeneca (AZN) receive proceeds from this withdrawal?

No proceeds are referenced in the filing excerpt. The Form 25 certifies rule compliance for delisting; it does not state any issuance, sale, cash proceeds, or use of proceeds related to the withdrawal.

Which securities were removed from NYSE listing for AstraZeneca (AZN)?

The filing identifies the "0.700% Notes due 2026." The notification references that class of securities as the subject of the voluntary withdrawal and removal from listing and/or registration.

Does the Form 25 filing indicate regulatory noncompliance or enforcement actions?

No enforcement action is stated in the excerpt. The Exchange certifies it complied with 17 CFR 240.12d2-2 and the issuer complied with NYSE rules for voluntary withdrawal; no penalties or violations are disclosed.

Who signed the Form 25 for the NYSE in this filing?

Tyler Mastronardi, Analyst, Market Watch, is shown as the signatory representing New York Stock Exchange LLC certifying reasonable grounds for the Form 25 filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

UNITED STATES

OMB APPROVAL

OMB Number:			3235-0080
Expires:	March 31, 2018
Estimated average burden
hours per response:			1.7

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 25

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number

001-11960

Issuer:	ASTRAZENECA PLC
Exchange:	NEW YORK STOCK EXCHANGE LLC

(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

Address:	1 FRANCIS CRICK AVENUE
	Cambridge		CB2 0AA
Telephone number:					+44 20 3749 5000

(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)

Guarantor of the 0.700% Notes due 2026

(Description of class of securities)

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

17 CFR 240.12d2-2(a)(1)

17 CFR 240.12d2-2(a)(2)

17 CFR 240.12d2-2(a)(3)

17 CFR 240.12d2-2(a)(4)

Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. ¹

Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

Pursuant to the requirements fo the Securities Exchange Act of 1934, NEW YORK STOCK EXCHANGE LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

2026-04-08	By	Tyler Mastronardi		Analyst, Market Watch
Date		Name		Title

¹ Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.